Categories
Alembic Pharmaceuticals Limited — Updates, 14-05-2026: Press Release
14-05-2026 · 10:08 am
Alembic Pharma received USFDA tentative approval for Darolutamide Tablets, 300 mg, for prostate cancer. This drug has an estimated market size of US$ 3,155 million, indicating a significant potential revenue stream.
No comments yet. Be the first to comment!